GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Macrogen 038290.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

11,050

+0.45%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Macrogen

Its shares trade on KOSDAQ under the ticker 038290.KQ. It has been listed since 22 February 2000. In the fiscal year to 31 December 2025, it reported revenue of ₩195.27bn and net income of ₩2.03bn. At that date it held total assets of ₩351.62bn and shareholders' equity of ₩157.26bn.

Macrogen, Inc. engages in the provision genetic research and biotechnology services. The company is headquartered in Seoul, Seoul. The company went IPO on 2000-02-22. The firm operates its business through four divisions: deoxyribonucleic acid (DNA) sequencing division, DNA chips division, transgenic and knockout mouse division and oligonucleotide DNA division. Its DNA sequencing division provides genome sequencing analysis services. Its DNA chips division develops DNA chips products, such as Illumina chips, MacArray chips and customized chips. Its transgenic and knockout mouse division offers gene engineering services. Its oligonucleotide DNA division offers oligonucleotide DNA manufacturing services. The firm operates its business within domestic market and in overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
22 Feb 2000

Leadership

Pay as last reported

  • Jeong Seon SeoChairman of the Board, since 2005
  • Chang Hun KimChief Executive Officer, Director, since 2022
  • Ji Yeong MoonChief Financial Officer, Director, since 2013
  • Han Seong JungInternal Auditor
  • Seok Hwa KimDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Seoul, South Korea
  • Operates through four specialized divisions including DNA sequencing and DNA chips
  • Provides genome sequencing analysis and gene engineering services

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No details on financial performance or market share provided
  • No information on competitive advantages or unique technologies

Opportunities

  • Expanding domestic and overseas markets for genetic research services
  • Growing demand for DNA sequencing and biotechnology services
  • Potential for new product development in DNA chips and oligonucleotide DNA

Threats

  • No specific threats mentioned in the provided information
  • No details on regulatory challenges or market competition
  • No information on potential economic or industry downturns

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.